Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status

Abstract Acute myeloid leukemia (AML) lacks effective prognostic markers. While lymphocyte subsets are recognized as valuable predictive indicators in hematologic malignancies, their role in AML remains largely unexplored, particularly during different stages of AML. Our study analyzed the levels an...

Full description

Saved in:
Bibliographic Details
Main Authors: Xunyi Jiao, Ji Zhou, Xue Liang, Jinli Zhu, Meng Xiao, Yangyang Ding, Qianshan Tao, Hao Xiao, Yingwei Li, Huiping Wang, Zhimin Zhai
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-01600-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850273580535775232
author Xunyi Jiao
Ji Zhou
Xue Liang
Jinli Zhu
Meng Xiao
Yangyang Ding
Qianshan Tao
Hao Xiao
Yingwei Li
Huiping Wang
Zhimin Zhai
author_facet Xunyi Jiao
Ji Zhou
Xue Liang
Jinli Zhu
Meng Xiao
Yangyang Ding
Qianshan Tao
Hao Xiao
Yingwei Li
Huiping Wang
Zhimin Zhai
author_sort Xunyi Jiao
collection DOAJ
description Abstract Acute myeloid leukemia (AML) lacks effective prognostic markers. While lymphocyte subsets are recognized as valuable predictive indicators in hematologic malignancies, their role in AML remains largely unexplored, particularly during different stages of AML. Our study analyzed the levels and changes of lymphocyte subsets in AML patients at newly diagnosed (ND) and first complete remission (CR) status, and explored the correlation between lymphocyte subsets and prognosis in different disease stages. Flow cytometry detected peripheral blood lymphocyte subsets in 145 ND AML patients, 125 CR AML patients, and 47 healthy controls (HCs). Dynamic testing was conducted on 28 AML patients at both ND and CR status. Our study found significant differences in lymphocyte subsets between ND, CR, and HCs, with notable changes in CD3+T, CD4+T, CD8+T, effector T (Teff), B, and natural killer (NK) cells between ND and CR status. Low frequencies of CD8+T below HCs thresholds and high regulatory T cell (Treg) frequency above HCs thresholds in the ND group, were independent risk factors for non-response to treatment. ROC curves evaluated the prognostic value of lymphocyte subsets and established cutoff values. Lymphocyte subsets in the ND group were not significantly associated with relapse or survival. Low absolute counts of CD3+T, B, and NK cells in the CR group were linked to AML relapse, and a low NK cell count was an independent predictor of overall survival (OS). Lymphocyte subsets can act as prognostic biomarkers, and their dynamic monitoring predicts treatment response, relapse, and survival in AML.
format Article
id doaj-art-ed9fac00656a44f6b19dfc53ef12f184
institution OA Journals
issn 2045-2322
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-ed9fac00656a44f6b19dfc53ef12f1842025-08-20T01:51:27ZengNature PortfolioScientific Reports2045-23222025-05-0115111510.1038/s41598-025-01600-3Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission statusXunyi Jiao0Ji Zhou1Xue Liang2Jinli Zhu3Meng Xiao4Yangyang Ding5Qianshan Tao6Hao Xiao7Yingwei Li8Huiping Wang9Zhimin Zhai10Department of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Epidemiology and Health Statistics, Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Hematology, The Second Affiliated Hospital of Anhui Medical UniversityAbstract Acute myeloid leukemia (AML) lacks effective prognostic markers. While lymphocyte subsets are recognized as valuable predictive indicators in hematologic malignancies, their role in AML remains largely unexplored, particularly during different stages of AML. Our study analyzed the levels and changes of lymphocyte subsets in AML patients at newly diagnosed (ND) and first complete remission (CR) status, and explored the correlation between lymphocyte subsets and prognosis in different disease stages. Flow cytometry detected peripheral blood lymphocyte subsets in 145 ND AML patients, 125 CR AML patients, and 47 healthy controls (HCs). Dynamic testing was conducted on 28 AML patients at both ND and CR status. Our study found significant differences in lymphocyte subsets between ND, CR, and HCs, with notable changes in CD3+T, CD4+T, CD8+T, effector T (Teff), B, and natural killer (NK) cells between ND and CR status. Low frequencies of CD8+T below HCs thresholds and high regulatory T cell (Treg) frequency above HCs thresholds in the ND group, were independent risk factors for non-response to treatment. ROC curves evaluated the prognostic value of lymphocyte subsets and established cutoff values. Lymphocyte subsets in the ND group were not significantly associated with relapse or survival. Low absolute counts of CD3+T, B, and NK cells in the CR group were linked to AML relapse, and a low NK cell count was an independent predictor of overall survival (OS). Lymphocyte subsets can act as prognostic biomarkers, and their dynamic monitoring predicts treatment response, relapse, and survival in AML.https://doi.org/10.1038/s41598-025-01600-3Lymphocyte subsetsAcute myeloid leukemiaPrognosis
spellingShingle Xunyi Jiao
Ji Zhou
Xue Liang
Jinli Zhu
Meng Xiao
Yangyang Ding
Qianshan Tao
Hao Xiao
Yingwei Li
Huiping Wang
Zhimin Zhai
Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
Scientific Reports
Lymphocyte subsets
Acute myeloid leukemia
Prognosis
title Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
title_full Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
title_fullStr Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
title_full_unstemmed Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
title_short Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
title_sort dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status
topic Lymphocyte subsets
Acute myeloid leukemia
Prognosis
url https://doi.org/10.1038/s41598-025-01600-3
work_keys_str_mv AT xunyijiao dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT jizhou dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT xueliang dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT jinlizhu dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT mengxiao dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT yangyangding dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT qianshantao dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT haoxiao dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT yingweili dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT huipingwang dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus
AT zhiminzhai dynamicmonitoringoflymphocytesubsetsatdifferentdiseasestagescanpredicttheprognosisofacutemyeloidleukemiaespeciallyincompleteremissionstatus